ProAxsis abstracts at 2017 American Thoracic Society Conference

Date : May 05, 2017

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th in Washington DC. The company has had three abstracts accepted for presentation by the conference review committee, details of which are below:

The Development of Novel ProteaseTags® for the Capture and Disclosure of Mast Cell Tryptase A34-CLINICAL AND CELLULAR STUDIES IN ALLERGIC DISEASE Thematic Poster Session (presenting author Dr Timothy Ferguson) SUNDAY, MAY 21, 2017 9:15 AM-4:15 PM

The Development of a Novel ProteaseTag® Immunoassay for the Detection and Quantification of Active Plasmin  C78-FIBROSIS: MEDIATORS AND MODULATORS Thematic Poster Session (presenting author Dr Darragh McCafferty) TUESDAY, MAY 23, 2017 9:15 AM-4:15 PM

Development of NEATstik® - a Novel Lateral Flow Device for the Detection of Active Neutrophil Elastase in Patients with Respiratory Disease C74-ADVANCES IN TRANSLATIONAL COPD Thematic Poster Session (presenting author Dr Kelly Moffitt) TUESDAY, MAY 23, 2017 9:15 AM-4:15 PM

Dr David Ribeiro, CEO of ProAxsis, said: “What I find most exciting about the work we’re presenting at this year’s ATS Conference is the variety. We’re providing data on three of our R&D products, all of which are expected to launch before the end of 2017. Our first point-of-care test, NEATstik®, has the potential to re-invent how the risk of future exacerbations for patients with long-term chronic diseases such as COPD, bronchiectasis and CF, is monitored. We expect the active plasmin immunoassay to act as a biomarker of fibrosis in diseases such as IPF, and our tryptase assay should provide quantification of mast cell involvement in diseases such as asthma and COPD. We’re very grateful to Invest Northern Ireland, who have supported our development work on these two target proteases.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact